» Articles » PMID: 2488104

Pharmacokinetic and Pharmacodynamic Comparison of Conventional and Controlled Release Formulations of Metoprolol [correction of Motoprolol] in Healthy Chinese Subjects

Overview
Date 1989 Aug 1
PMID 2488104
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A double-blind, crossover comparison of the pharmacokinetics and pharmacodynamics of controlled-release metoprolol (CR) 100 mg and 200 mg, metoprolol plain tablet 100 mg, metoprolol Durules 200 mg, and placebo was carried out in 10 healthy Chinese subjects. Standardized treadmill exercise tests according to the Bruce protocol were performed at a steady state of medication, before and 2, 6, 12, and 24 hours after the dose, and multiple blood samples were collected for determination of the metoprolol concentration. The plasma metoprolol levels over 24 hours were more uniform after metoprolol CR than Durules and the plain tablet. The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively. The corresponding fluctuation incides were 1.1, 1.5, 2.2, and 5.0. The effects on exercise heart rate (EHR) were investigated at steady state. Metoprolol CR produced more even reduction in EHR over 24 hours than Durules and plain tablets. All four treatments gave similar maximal reduction in EHR of about 20% at 2 hours after the dose. In conclusion, once daily metoprolol CR showed almost even blood levels and provided relatively constant levels of beta1 blockade over 24 hours in healthy Chinese subjects.

Citing Articles

Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Tfelt-Hansen P, Agesen F, Pavbro A, Tfelt-Hansen J CNS Drugs. 2017; 31(5):389-403.

PMID: 28405886 DOI: 10.1007/s40263-017-0430-3.


Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Peters D, Benfield P Pharmacoeconomics. 1994; 6(4):370-400.

PMID: 10147474 DOI: 10.2165/00019053-199406040-00004.


A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.

Chen M, Yang C, Chen W, Lee C, Wu C, Liau C Cardiovasc Drugs Ther. 1995; 9(3):401-6.

PMID: 8527349 DOI: 10.1007/BF00879028.


Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.

Kaila T, Roivas L, Neuvonen P Eur J Clin Pharmacol. 1994; 46(3):237-42.

PMID: 8070504 DOI: 10.1007/BF00192555.


Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Plosker G, Clissold S Drugs. 1992; 43(3):382-414.

PMID: 1374320 DOI: 10.2165/00003495-199243030-00006.

References
1.
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G . Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988; 259(13):1976-82. View

2.
Johansson S, McCall M, Wilhelmsson C, Vedin J . Duration of action of beta blockers. Clin Pharmacol Ther. 1980; 27(5):593-601. DOI: 10.1038/clpt.1980.84. View

3.
Sandberg A, Ragnarsson G, Jonsson U, Sjogren J . Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR. Eur J Clin Pharmacol. 1988; 33 Suppl:S3-7. DOI: 10.1007/BF00578405. View

4.
Egstrup K, GUNDERSEN T, Harkonen R, Karlsson E, Lundgren B . The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. Eur J Clin Pharmacol. 1988; 33 Suppl:S45-9. DOI: 10.1007/BF00578412. View

5.
Olsson G, Rehnqvist N, Sjogren A, Erhardt L, LUNDMAN T . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol. 1985; 5(6):1428-37. DOI: 10.1016/s0735-1097(85)80360-0. View